Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Catharina Ziekenhuis Eindhoven
Eastern Cooperative Oncology Group
N.N. Alexandrov National Cancer Centre
N.N. Alexandrov National Cancer Centre
Fudan University
Novita Pharmaceuticals, Inc.
National Cancer Institute (NCI)
Cancer Research UK
Daiichi Sankyo
National Taiwan University Hospital
ARCAGY/ GINECO GROUP
Women's Hospital School Of Medicine Zhejiang University
Fudan University
RenJi Hospital
Cancer Research UK
Boston University
Cancer Research UK
Cancer Research UK
GE Healthcare
Sutro Biopharma, Inc.
L & L Bio Co., Ltd., Ningbo, China
Bio-Thera Solutions
University Health Network, Toronto
Fudan University
Fudan University
Fudan University
Mateon Therapeutics
Obstetrics & Gynecology Hospital of Fudan University
Bio-Thera Solutions
Shandong New Time Pharmaceutical Co., LTD
University of California, San Diego
Leiden University Medical Center
Tongji Hospital
Second Affiliated Hospital of Guangzhou Medical University
Kartos Therapeutics, Inc.
Cornell University
Second Affiliated Hospital of Wenzhou Medical University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
Gynecologic Oncology Trial & Investigation Consortium
Gynaecologisch Oncologisch Centrum Zuid
Fudan University
Zagazig University
Menoufia University
Odense University Hospital
Instituto Nacional de Salud Publica, Mexico
GOG Foundation
West China Second University Hospital
AB Science